Literature DB >> 27358112

Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia.

Blake S Moses1, Rebecca Evans1, William L Slone1, Debbie Piktel1, Ivan Martinez2, Michael D Craig1, Laura F Gibson3.   

Abstract

Acute lymphoblastic leukemia (ALL) has many features in common with normal B-cell progenitors, including their ability to respond to diverse signals from the bone marrow microenvironment (BMM) resulting in regulation of cell-cycle progression and survival. Bone marrow-derived cues influence many elements of both steady state hematopoiesis and hematopoietic tumor cell phenotypes through modulation of gene expression. miRNAs are one regulatory class of small noncoding RNAs that have been shown to be increasingly important in diverse settings of malignancy. In the current study, miRNA profiles were globally altered in ALL cells following exposure to primary human bone marrow niche cells, including bone marrow stromal cells (BMSC) and primary human osteoblasts (HOB). Specifically, mature miR-221 and miR-222 transcripts were decreased in ALL cells cocultured with BMSC or HOB, coincident with increased p27 (CDKN1B), a previously validated target. Increased p27 protein in ALL cells exposed to BMSC or HOB is consistent with accumulation of tumor cells in the G0 phase of the cell cycle and resistance to chemotherapy-induced death. Overexpression of miR-221 in ALL cells during BMSC or HOB coculture prompted cell-cycle progression and sensitization of ALL cells to cytotoxic agents, blunting the protective influence of the BMM. These novel observations indicate that BMM regulation of miR-221/222 contributes to marrow niche-supported tumor cell quiescence and survival of residual cells. IMPLICATIONS: Niche-influenced miR-221/222 may define a novel therapeutic target in ALL to be combined with existing cytotoxic agents to more effectively eradicate refractory disease that contributes to relapse. Mol Cancer Res; 14(10); 909-19. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27358112      PMCID: PMC5065748          DOI: 10.1158/1541-7786.MCR-15-0474

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  53 in total

1.  Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models.

Authors:  D C Chow; L A Wenning; W M Miller; E T Papoutsakis
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

2.  Bone marrow microenvironment modulation of acute lymphoblastic leukemia phenotype.

Authors:  Blake S Moses; William L Slone; Patrick Thomas; Rebecca Evans; Debbie Piktel; Peggi M Angel; Callee M Walsh; Pamela S Cantrell; Stephanie L Rellick; Karen H Martin; James W Simpkins; Laura F Gibson
Journal:  Exp Hematol       Date:  2015-09-25       Impact factor: 3.084

3.  microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma.

Authors:  Ruey-Jen Lin; You-Chin Lin; Jeremy Chen; Huan-Hsien Kuo; Yuan-Yan Chen; Mitchell B Diccianni; Wendy B London; Chih-Hao Chang; Alice L Yu
Journal:  Cancer Res       Date:  2010-08-30       Impact factor: 12.701

4.  MiR-185 acts as a tumor suppressor by targeting AKT1 in non-small cell lung cancer cells.

Authors:  Shuai Li; Yulian Ma; Xinfang Hou; Ying Liu; Ke Li; Shuning Xu; Jufeng Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche.

Authors:  Yusuke Shiozawa; Elisabeth A Pedersen; Russell S Taichman
Journal:  Exp Hematol       Date:  2009-11-14       Impact factor: 3.084

Review 6.  Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting.

Authors:  Francesca Chiarini; Annalisa Lonetti; Camilla Evangelisti; Francesca Buontempo; Ester Orsini; Cecilia Evangelisti; Alessandra Cappellini; Luca M Neri; James A McCubrey; Alberto M Martelli
Journal:  Biochim Biophys Acta       Date:  2015-09-01

7.  Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells.

Authors:  A Manabe; K G Murti; E Coustan-Smith; M Kumagai; F G Behm; S C Raimondi; D Campana
Journal:  Blood       Date:  1994-02-01       Impact factor: 22.113

8.  The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination.

Authors:  H W Van den Berg; Z R Desai; R Wilson; G Kennedy; J M Bridges; R G Shanks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active Akt.

Authors:  Lin Wang; James E Fortney; Laura F Gibson
Journal:  Leuk Res       Date:  2004-07       Impact factor: 3.156

Review 10.  MicroRNAs in hematopoietic development.

Authors:  Sara Montagner; Lorenzo Dehó; Silvia Monticelli
Journal:  BMC Immunol       Date:  2014-03-31       Impact factor: 3.615

View more
  18 in total

1.  Novel compounds that target lipoprotein lipase and mediate growth arrest in acute lymphoblastic leukemia.

Authors:  Rajesh R Nair; Werner J Geldenhuys; Debbie Piktel; Prabodh Sadana; Laura F Gibson
Journal:  Bioorg Med Chem Lett       Date:  2018-03-23       Impact factor: 2.823

Review 2.  Tissue Elasticity Bridges Cancer Stem Cells to the Tumor Microenvironment Through microRNAs: Implications for a "Watch-and-Wait" Approach to Cancer.

Authors:  Shengwen Calvin Li; Long T Vu; Jane Jianying Luo; Jiang F Zhong; Zhongjun Li; Brent A Dethlefs; William G Loudon; Mustafa H Kabeer
Journal:  Curr Stem Cell Res Ther       Date:  2017       Impact factor: 3.828

Review 3.  Cancer-Derived Extracellular Vesicle-Associated MicroRNAs in Intercellular Communication: One Cell's Trash Is Another Cell's Treasure.

Authors:  Joseph Mills; Marina Capece; Emanuele Cocucci; Anna Tessari; Dario Palmieri
Journal:  Int J Mol Sci       Date:  2019-12-04       Impact factor: 5.923

4.  The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia.

Authors:  Werner J Geldenhuys; Rajesh R Nair; Debbie Piktel; Karen H Martin; Laura F Gibson
Journal:  J Pharmacol Exp Ther       Date:  2019-04-22       Impact factor: 4.030

Review 5.  In Vitro and In Vivo Modeling of Normal and Leukemic Bone Marrow Niches: Cellular Senescence Contribution to Leukemia Induction and Progression.

Authors:  Myriam Janeth Salazar-Terreros; Jean-Paul Vernot
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

6.  Pyrvinium Pamoate Use in a B cell Acute Lymphoblastic Leukemia Model of the Bone Tumor Microenvironment.

Authors:  Rajesh R Nair; Debbie Piktel; Quincy A Hathaway; Stephanie L Rellick; Patrick Thomas; Pushkar Saralkar; Karen H Martin; Werner J Geldenhuys; John M Hollander; Laura F Gibson
Journal:  Pharm Res       Date:  2020-01-27       Impact factor: 4.200

Review 7.  The role of RNA processing and regulation in metastatic dormancy.

Authors:  Kimberly A Parker; Nathaniel J Robinson; William P Schiemann
Journal:  Semin Cancer Biol       Date:  2021-03-26       Impact factor: 15.707

8.  SOCS1 regulates hepatic regenerative response and provides prognostic makers for acute obstructive cholangitis.

Authors:  Jianhua Yu; Weiguang Zhang; Hongwei Qian; Haijun Tang; Weiguo Lin; Baochun Lu
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

Review 9.  The regulatory role of microRNAs in angiogenesis-related diseases.

Authors:  Li-Li Sun; Wen-Dong Li; Feng-Rui Lei; Xiao-Qiang Li
Journal:  J Cell Mol Med       Date:  2018-06-29       Impact factor: 5.310

10.  Inhibition of MicroRNA-221 and 222 Enhances Hematopoietic Differentiation from Human Pluripotent Stem Cells via c-KIT Upregulation.

Authors:  Ji Yoon Lee; MyungJoo Kim; Hye-Ryeon Heo; Kwon-Soo Ha; Eun-Taek Han; Won Sun Park; Se-Ran Yang; Seok-Ho Hong
Journal:  Mol Cells       Date:  2018-11-01       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.